AbbVie Inc., a biopharmaceutical company based in North Chicago, Illinois, with a market cap of $385.2 billion, focuses on innovative medicines in various therapeutic areas. Despite lagging behind the market over the past year, the stock is up 22.1% YTD, outperforming the broader S&P 500 Index and iShares U.S. Healthcare ETF.

AbbVie reported better-than-expected Q3 earnings, with revenue growing 9.1% year-over-year to $15.8 billion, surpassing estimates by 1.2%. The adjusted EPS declined but beat analyst expectations. The company raised its fiscal 2025 adjusted EPS guidance to between $10.61 and $10.65. Analysts predict EPS growth of 4.6% this fiscal year.

Of the 28 analysts covering AbbVie, the consensus rating is a “Moderate Buy,” with 15 “Strong Buy,” two “Moderate Buy,” and 11 “Hold” ratings. This is slightly less bullish than a month ago, with 16 analysts suggesting a “Strong Buy” rating. JPMorgan Chase & Co. maintained an “Overweight” rating on AbbVie with a price target of $260, indicating a 22.2% potential upside.

Read more at Yahoo Finance: Do Wall Street Analysts Like AbbVie Stock?